Targeting the 'Janus face' of the B2-bradykinin receptor

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 10, 2013, Pages 1145-1166

  Blaes, Nelly ^a   Girolami, Jean Pierre ^a  

^a University Hospital of Toulouse   (France)

Author keywords

Agonism; Angiotensin; Angiotensin converting enzyme; Antagonism; B2 kinin receptor; Bradykinin; Cardiovascular; Diabetes; Hypertension; Inflammation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYSTROPHIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN; KININ; NITRIC OXIDE SYNTHASE;

ACUTE HEART INFARCTION; ALZHEIMER DISEASE; ANGIOGENESIS; ANGIONEUROTIC EDEMA; BLOOD VESSEL WALL; BRAIN CANCER; BRAIN EDEMA; CARDIOMYOPATHY; CHAGAS DISEASE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DUCHENNE MUSCULAR DYSTROPHY; ENDOTHELIUM; ENDOTHELIUM CELL; GENE MUTATION; GLAUCOMA; HEART DISEASE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INFECTION; INFLAMMATION; INNATE IMMUNITY; ISCHEMIA; ISCHEMIC HEART DISEASE; NEOPLASM; NOCICEPTION; NONHUMAN; PAIN; PARASITOSIS; PROTEIN EXPRESSION; REVIEW; SEPTIC SHOCK; TISSUE INJURY; TRAUMATIC BRAIN INJURY; WESTERN BLOTTING;

ANIMALS; HUMANS; RECEPTOR, BRADYKININ B2;

EID: 84884585186     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.827664     Document Type: Review

References (150)

1. Moreau ME, Garbacki N, Molinaro G, et al. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 2005;99:6-38
2. Kakoki M, Smithies O. The kallikrein system in health and disease of the kidney. Kidney Int 2009;75:1019-30
3. Kayashima Y, Smithies O, Kakoki M. The kallikrein-kinin system and oxidative stress. Curr Opin Nephrol Hypertens 2012;21:92-6
4. Petho G, Reeh PW. Sensory and signaling mechanisms of bradykinin, eicosamoids, platelet-activating factor and nitric-oxide in peripheral nociceptors. Physiol Rev 2012;92:1699-775
5. Alhenc-Gelas F, Bouby N, Richer C, et al. Kinin as therapeutic agents in cardiovascular and renal diseases. Curr Pharm Des 2011;17:2654-62
6. Figueroa CD Ehrenfeld P, Bhoola KD. Kinin receptor as targets for cancer therapy. Expert Opin Ther Targets 2012;16:299-312
7. Regoli D, Plante GE, Gobeil F Jr. Impact of kinin in the treatment of cardiovascular diseases. Pharmacol Ther 2012;135:94-111
8. Fincham CI, Bressan A, Paris M, et al. Bradykinin receptor antagonists-a review of the patent literature 2005-2008. Expert Opin Ther Patents 2009;19:919-41
9. Whalley ET, Figueroa CD, Gera L, Bhoola KD. Discovery and therapeutic potential of kinin receptor antagonists. Expert Opin Drug Discov 2012;7:1129-48
10. Charignon D, Spath P, Martin L, Drouet C. Icatibant, the bradykinin B2 receptor antagonist with target to the interconnected kinin systems. Expert Opin Pharmacother 2012;13:2233-47
11. Erdos EG, Tan F, Skidgel RA. Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension 2010;55:214-20
12. Iwai M, Horiuchi M. Role of the ACE2/angiotensin1-7/Mas axis in the cardiovascular system. Hypertens Res 2010;33:1108-9
13. Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 1993;268:9496-503
14. Campbell DJ, Alexiou T, Xiao HD, et al. Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice. Hypertension 2004;43:854-9
15. Huang W, Gallois Y, Bouby N, et al. Genetically increased angiotensin I-converting enzyme level and renal complications in diabetic mouse. Proc Natl Acad Sci USA 2001;98:13330-4
16. Tschope C, Schultheiss HP, Walther T. Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade. J Cardiovasc Pharmacol 2002;39:478-87
17. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998;104:925-35
18. Tsutsumi Y, Matsubara H, Masaki H. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999;104:925-35
19. Siragy HM, Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 1999;33:1237-42
20. Zhu L, Carretero OA, Xu J, et al. Angiotensin II type 2 receptor-stimulated activation of plasma prekallikrein and bradykinin release: role of SHP-1. Am J Physiol Heart Circ Physiol 2012;302:H2553-9
21. Kurisu S, Ozono R, Oshima T, et al. Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 2003;41:99-107
22. Siragy HM, Inagami T, Ichiki T, Carey RM. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA 1999;96:6506-10
23. Verdonk K, Danser AH, van Esch JH. Angiotensin II type 2 receptor agonists: where should they be applied? Expert Opin Investig Drugs 2012;21:501-13
24. Padia SH, Carey RM. AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function. Pflugers Arch 2013;465:99-110
25. Paula RD, Lima CV, Khosla MC, Santos RA. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension 1995;26:1154-9
26. Lu J, Zhang Y, Shi J. Effects of intracerebroventricular infusion of angiotensin-(1-7) on bradykinin formation and the kinin receptor expression after focal cerebral ischemia-reperfusion in rats. Brain Res 2008;1219:127-35
27. Fraga-Silva RA, Ferreira AJ, Dos Santos RA. Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension. Curr Hypertens Rep 2013;15:31-8
28. Campbell DJ, Zhang Y, Kelly DJ, et al. Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart. Clin Exp Pharmacol Physiol 2011;38:623-31
29. Liao JK, Homcy CJ. The G proteins of the G alpha i and G alpha q family couple the bradykinin receptor to the release of endothelium-derived relaxing factor. J Clin Invest 1993;92:2168-72
30. Quitterer U, Lohse MJ. Crosstalk between Galpha(i)-and Galpha(q)-coupled receptors is mediated by Gbetagamma exchange. Proc Natl Acad Sci USA 1999;96:10626-31
31. Leeb-Lundberg FLM. Kinin receptor signaling and regulation. In: Bader M, editor. Kinins. De Gruyter Publisher; Berlin/Boston: 2012. p. 33-50
32. Nie M, Pang L, Inoue H, Knox AJ. Transcriptional regulation of cyclooxygenase 2 by bradykinin and interleukin-1beta in human airway smooth muscle cells: involvement of different promoter elements, transcription factors, and histone h4 acetylation. Mol Cell Biol 2003;23:9233-44
33. Chen BC, Yu CC, Lei HC, et al. Bradykinin B2 receptor mediates NF-kappaB activation and cyclooxygenase-2 expression via the Ras/Raf-1/ERK pathway in human airway epithelial cells. J Immunol 2004;173:5219-28
34. Liebmann C, Graness A, Boehmer A, et al. Tyrosine phosphorylation of GS alpha and inhibition of bradykinin-induced activation of the cyclic AMP pathway in A431 cells by epidermal growth factor receptor. J Biol Chem 1996;271:31098-105
35. Burch RM, Axelrod J. Dissociation of bradykinin-induced prostaglandin formation from phosphatidylinositol turnover in Swiss 3T3 fibroblasts: evidence for G protein regulation of phospholipase A2. Proc Natl Acad Sci USA 1987;84:6374-8
36. Lal MA, Proulx PR, Hebert RL. A role for PKC epsilon and MAP kinase in bradykinin-induced arachidonic acid release in rabbit CCD cells. Am J Physiol 1998;274:F728-35
37. Slivka SR, Insel PA. Phorbol ester and neomycin dissociate bradykinin receptor-mediated arachidonic acid release and polyphosphoinositide hydrolysis in Madin-Darby canine kidney cells. Evidence that bradykinin mediates noninterdependent activation of phospholipases A2 and C. J Biol Chem 1988;263:14640-7
38. Pizard A, Blaukat A, Muller-Esterl W, et al. Bradykinin-induced internalization of the human B2 receptor requires phosphorylation of three serine and two threonine residues at its carboxyl tail. J Biol Chem 1999;274:12738-47
39. Zimmerman B, Simaan M, Akoume MY, et al. Role of - arrestins in bradykinin B2 receptor-mediated signalling. Cell Signal 2011;23:648-59
40. Duchene J, Schanstra JP, Pecher C, et al. A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation. J Biol Chem 2002;277:40375-83
41. Dey M, Baldys A, Sumter DB, et al. Bradykinin decreases podocyte permeability through ADAM17-dependent epidermal growth factor receptor activation and zonula occludens-1 rearrangement. J Pharmacol Exp Ther 2010;334:775-83
42. Zhang X, Mak S, Li L, et al. Direct inhibition of the cold-activated TRPM8 ion channel by Gaq. Nat Cell Biol 2012;14:851-8
43. AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 2000;407:94-8
44. Wilson PC, Lee MH, Appleton KM, et al. The arrestin-selective angiotensin AT1 receptor agonist [Sar1,Ile4,Ile8]-AngII negatively regulates bradykinin B2 receptor signaling via AT1-B2 receptor heterodimers. J Biol Chem 2013;288:18872-84
45. Abadir PM, Periasamy A, Carey RM, Siragy HM. Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension 2006;48:316-22
46. Fleming I. Signaling by the angiotensin-converting enzyme. Circ Res 2006;98:887-96
47. Arganaraz GA, Silva JA Jr, Perosa SR, et al. The synthesis and distribution of the kinin B1 and B2 receptors are modified in the hippocampus of rats submitted to pilocarpine model of epilepsy. Brain Res 2004;1006:114-25
48. Savard M, Barbaz D, Belanger S, et al. Expression of endogenous nuclear bradykinin B2 receptors mediating signaling in immediate early gene activation. J Cell Physiol 2008;216:234-44
49. Leschner J, Wennerberg G, Feierler J, et al. Interruption of the ionic lock in the bradykinin B2 receptor results in constitutive internalization and turns several antagonists into strong agonists. J Pharmacol Exp Ther 2013;344:85-95
50. Shen B, Harrison-Bernard LM, Fuller AJ, et al. The Bradykinin B2 receptor gene is a target of angiotensin II type 1 receptor signaling. J Am Soc Nephrol 2007;18:1140-9
51. Souza P, Brechter A, Reis R, et al. IL-4 and IL-13 inhibit IL-1b and TNF-a induced kinin B1 and B2 receptors through a STAT6-dependent mechanism. Br J Pharmacol 2013;169:400-12
52. Rastelli VM, Oliveira MA, dos Santos R, et al. Enalapril treatment corrects the reduced response to bradykinin in diabetes increasing the B2 protein expression. Peptides 2008;29:404-11
53. Rodrigues ES, Silva RF, Martin RP, et al. Evidence that kinin B2 receptor expression is upregulated by endothelial overexpression of B1 receptors. Peptides 2013;42C:1-7
54. Candelario J, Chachisvilis M. Activity of bradykinin B2 receptor is regulated by long-chain polyunsaturated fatty acids. PLoS One 2013;8(6):e68151. Print 2013
55. Bodin S, Chollet C, Goncalves-Mendes N, et al. Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney Int 2009;76:395-403
56. Murphey LJ, Malave HA, Petro J, et al. Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans. J Pharmacol Exp Ther 2006;318:1287-92
57. Cuculi F, Erne P. Combined neutral endopeptidase inhibitors. Expert Opin Investig Drugs 2011;20:457-63
58. Belanger S, Bovenzi V, Cote J, et al. Structure-activity relationships of novel peptide agonists of the human bradykinin B2 receptor. Peptides 2009;30:777-87
59. Sarin H, Kanevsky AS, Fung SH, et al. Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. J Transl Med 2009;7:33
60. Savard M, Labonte J, Dubuc C, et al. Further pharmacological evaluation of a novel synthetic peptide bradykinin B2 receptor agonist. Biol Chem 2013;394:353-60
61. Kellermeyer RW, Graham RC Jr. Kinins-possible physiologic and pathologic roles in man. N Engl J Med 1968;279:754-9
62. Margolius HS. Tissue kallikreins and kinins: regulation and roles in hypertensive and diabetic diseases. Annu Rev Pharmacol Toxicol 1989;29:343-64
63. Duka A, Duka I, Gao G, et al. Role of bradykinin B1 and B2 receptors in normal blood pressure regulation. Am J Physiol Endocrinol Metab 2006;291:E268-74
64. Alfie ME, Yang XP, Hess F, Carretero OA. Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun 1996;224:625-30
65. Cervenka L, Maly J, Karasova L, et al. Angiotensin II-induced hypertension in bradykinin B2 receptor knockout mice. Hypertension 2001;37:967-73
66. Tsuchida S, Miyazaki Y, Matsusaka T, et al. Potent antihypertrophic effect of the bradykinin B2 receptor system on the renal vasculature. Kidney Int 1999;56:509-16
67. Seccia TM, Belloni AS, Guidolin D, et al. The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension. J Hypertens 2006;24:1419-27
68. Schanstra JP, Neau E, Drogoz P, et al. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 2002;110:371-9
69. Chao J, Li HJ, Yao YY, et al. Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. Hypertension 2007;49:490-7
70. Ardiles LG, Cardenas A, Burgos ME, et al. Antihypertensive and renoprotective effect of the kinin pathway activated by potassium in a model of salt-sensitivity following overload proteinuria. Am J Physiol Renal Physiol 2013;304:F1399-410
71. Taraseviciene-Stewart L, Scerbavicius R, Stewart JM, et al. Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides 2005;26:1292-300
72. Krankel N, Katare RG, Siragusa M, et al. Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularisation potential. Circ Res 2008;103:1335-43
73. Hirooka K, Shiraga F. Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma. Clin Ophthalmol 2007;1:217-23
74. Sharif NA. United States Patent Sharif. Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma. US8263555B2; 2012
75. Yasuyoshi H, Kashii S, Zhang S, et al. Protective effect of bradykinin against glutamate neurotoxicity in cultured rat retinal neurons. Invest Ophthalmol Vis Sci 2000;41:2273-8
76. Nolly H, Carbini LA, Scicli G, et al. A local kallikrein-kinin system is present in rat hearts. Hypertension 1994;23:919-23
77. Spillmann F, Altmann C, Scheeler M, et al. Regulation of cardiac bradykinin B1-and B2-receptor mRNA in experimental ischemic, diabetic, and pressure-overload-induced cardiomyopathy. Int Immunopharmacol 2002;2:1823-32
78. Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 1994;270:681-9
79. Penna C, Mancardi D, Rastaldo R, et al. Intermittent activation of bradykinin B2 receptors and mitochondrial KATP channels trigger cardiac postconditioning through redox signaling. Cardiovasc Res 2007;75:168-77
80. Gross GJ, Baker JE, Moore J, et al. Abdominal surgical incision induces remote preconditioning of trauma (RPCT) via activation of bradykinin receptors (BK2R) and the cytochrome P450 epoxygenase pathway in canine hearts. Cardiovasc Drugs Ther 2011;25:517-22
81. Xi L, Das A, Zhao ZQ, et al. Loss of myocardial ischemic postconditioning in adenosine A1 and bradykinin B2 receptors gene knockout mice. Circulation 2008;118:S32-7
82. Feng J, Bianchi C, Sandmeyer JL, Sellke FW. Bradykinin preconditioning improves the profile of cell survival proteins and limits apoptosis after cardioplegic arrest. Circulation 2005;112:I190-5
83. Jones WK, Fan GC, Liao S, et al. Peripheral nociception associated with surgical incision elicits remote nonischemic cardioprotection via neurogenic activation of protein kinase C signaling. Circulation 2009;120:S1-9
84. Jalowy A, Schulz R, Dorge H, et al. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 1998;32:1787-96
85. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997;99:1926-35
86. Duka A, Kintsurashvili E, Duka I, et al. Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors. Hypertension 2008;51:1352-7
87. Yao YY, Yin H, Shen B, et al. Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction. J Card Fail 2007;13:588-96
88. Yin H, Chao J, Bader M, Chao L. Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides 2007;28:1383-9
89. Marketou M, Kintsurashvili E, Papanicolaou KN, et al. Cardioprotective effects of a selective B(2) receptor agonist of bradykinin post-acute myocardial infarct. Am J Hypertens 2010;23:562-8
90. Potier L, Waeckel L, Vincent MP, et al. Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes. J Pharmacol Exp Ther 2013;346:23-30
91. Wei CC, Chen Y, Powell LC, et al. Cardiac kallikrein-kinin system is upregulated in chronic volume overload and mediates an inflammatory induced collagen loss. PLoS ONE 2012;7:e40110
92. Sanchez de Miguel L, Neysari S, Jakob S, et al. B2-kinin receptor plays a key role in B1-, angiotensin converting enzyme inhibitor-, and vascular endothelial growth factor-stimulated in vitro angiogenesis in the hypoxic mouse heart. Cardiovasc Res 2008;80:106-13
93. Krankel N, Kuschnerus K, Muller et al. Novel insights into the critical role of bradykinin and the kinin b2 receptor for vascular recruitment of circulating endothelial repair-promoting mononuclear cell subsets: alterations in patients with coronary disease. Circulation 2013;127:594-603
94. Qin C, Du JQ, Tang JS, Foreman RD. Bradykinin is involved in the mediation of cardiac nociception during ischemia through upper thoracic spinal neurons. Curr Neurovasc Res 2009;6:89-94
95. Fu LW, Longhurst JC. Bradykinin and thromboxane A2 reciprocally interact to synergistically stimulate cardiac spinal afferents during myocardial ischemia. Am J Physiol Heart Circ Physiol 2010;298:H235-44
96. Koba S, Xing J, Sinoway LI, Li J. Bradykinin receptor blockade reduces sympathetic nerve response to muscle contraction in rats with ischemic heart failure. Am J Physiol Heart Circ Physiol 2010;298:H1438-44
97. Tonduangu D, Hittinger L, Ghaleh B, et al. Chronic infusion of bradykinin delays the progression of heart failure and preserves vascular endothelium-mediated vasodilation in conscious dogs. Circulation 2004;109:114-19
98. Campbell DJ, Kladis A, Zhang Y, et al. Increased tissue kallikrein levels in type 2 diabetes. Diabetologia 2010;53:779-85
99. Rett K, Wicklmayr M, Dietze GJ, Haring HU. Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes 1996;45:S66-9
100. Barros CC, Haro A, Russo FJ, et al. Altered glucose homeostasis and hepatic function in obese mice deficient for both kinin receptor genes. PLoS ONE 2012;7:e40573
101. Merchant ML, Niewczas MA, Ficociello LH, et al. Plasma kininogen and kininogen fragments are biomarkers of progressive renal decline in type 1 diabetes. Kidney Int 2013;83:1177-84
102. Kakoki M, Sullivan KA, Backus C, et al. Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in akita diabetic mice. Proc Natl Acad Sci USA 2010;107:10190-5
103. Blaes N, Pecher C, Mehrenberger M, et al. Bradykinin inhibits high glucoseand growth factor-induced collagen synthesis in mesangial cells through the B2-kinin receptor. Am J Physiol Renal Physiol 2012;303:F293-303
104. Tan Y, Keum JS, Wang B, et al. Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am J Physiol Renal Physiol 2007;293:F1026-35
105. Couture R, Girolami JP. Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. Eur J Pharmacol 2004;500:467-85
106. Allard J, Buleon M, Cellier E, et al. ACE inhibitor reduces growth factor receptor expression and signaling but also proteinuria through B2-kinin glomerular receptor activation in diabetic rats. Am J Physiol Renal Physiol 2007;293:F1083-92
107. Buleon M, Allard J, Jaafar A, et al. Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model. Am J Physiol Renal Physiol 2008;294:F1249-56
108. Kwak SJ, Paeng J, Kim do H, et al. Local kallikrein-kinin system is involved in podocyte apoptosis under diabetic conditions. Apoptosis 2011;16:478-90
109. Tschope C, Westermann D. Development of diabetic cardiomyopathy and the kallikrein-kinin system-new insights from B1 and B2 receptor signaling. Biol Chem 2008;389:707-11
110. Adam A, Leclair P, Montpas N, et al. Altered cardiac bradykinin metabolism in experimental diabetes caused by the variations of angiotensin-converting enzyme and other peptidases. Neuropeptides 2010;44:69-75
111. Wende AR, Soto J, Olsen CD, et al. Loss of bradykinin signaling does not accelerate the development of cardiac dysfunction in type 1 diabetic akita mice. Endocrinology 2010;15:3536-42
112. Montanari D, Yin H, Dobrzynski E, et al. Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes 2005;54:1573-80
113. Clermont A, Chilcote TJ, Kita T, et al. Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats. Diabetes 2011;60:1590-8
114. Pouliot M, Talbot S, Senecal J, et al. Ocular application of the kinin B1 receptor antagonist LF22-0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats. PLoS One 2012;7:e33864
115. Bossi F, Peerschke EI, Ghebrehiwet B, Tedesco F. Cross-talk between the complement and the kinin system in vascular permeability. Immunol Lett 2011;140:7-13
116. Oschatz C, Maas C, Lecher B, et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011;34:258-68
117. Maurer M, Bader M, Bas M, et al. New topics in bradykinin research. Allergy 2011;66:1397-406
118. Valenti C, Giuliani S, Cialdai C, et al. Fasitibant chloride, a kinin B2 receptor antagonist, and dexamethasone interact to inhibit carrageenan-induced inflammatory arthritis in rats. Br J Pharmacol 2012;166:1403-10
119. Sabatini F, Luppi F, Petecchia L, et al. Bradykinin-induced asthmatic fibroblast/myofibroblast activities via bradykinin B2 receptor and different MAPK pathways. Eur J Pharmacol 2013;710:100-9
120. Fox AJ, Lalloo UG, Belvisi MG, et al. Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nat Med 1996;2:814-17
121. Broadley KJ, Blair AE, Kidd EJ, et al. Bradykinin-induced lung inflammation and bronchoconstriction role in parainfluenze-3 virus-induced inflammation and airway hyperreactivity. J Pharmacol Exp Ther 2010;681-92
122. Bjorkqvist J, Sala-Cunill A, Renne T. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost 2013;109:368-74
123. Caballero T, Baeza ML, Cabanas R, et al. Spanish Study Group on Bradykinin-Induced Angioedema (SGBA). Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. J Investig Allergol Clin Immunol 2011;21:422-41
124. Bernstein JA, Moellman J. Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema. Int J Emerg Med 2012;5:39
125. Farkas H. Current pharmacotherapy of bradykinin-mediated angioedema. Expert Opin Pharmacother 2013;14571-86
126. Joseph K, Kaplan AP. Formation of bradykinin: a major contributor to the innate inflammatory response. Adv Immunol 2005;86:159-208
127. Aliberti J, Viola JP, Vieira-de-Abreu A, et al. Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization. J Immunol 2003;170:5349-53
128. Nico D, Feijo DF, Maran N, et al. Resistance to visceral leishmaniasis is severely compromised in mice deficient of bradykinin B2-receptors. Parasitol Vectors 2012;5:261-5
129. Monteiro AC, Scovino A, Raposo S, et al. Kinin danger signals proteolytically released by gingipain induce Fimbriae-specific IFN-gamma-and IL-17-producing T cells in mice infected intramucosally with Porphyromonas gingivalis. J Immunol 2009;18:3700-11
130. Cayla C, Todiras M, Iliescu R, et al. Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J 2007;21:1689-98
131. Morinelli TA, Webb JG, Jaffa AA, et al. A metabolic fragment of bradykinin, Arg-Pro-Pro-Gly-Phe, protects against the deleterious effects of lipopolysaccharide in rats. J Pharmacol Exp Ther 2001;296:71-6
132. Scharfstein J, Andrade D, Svensjo E, et al. The kallikrein-kinin system in experimental Chagas disease: a paradigm to investigate the impact of inflammatory edema on GPCR-mediated pathways of host cell invasion by Trypanosoma cruzi. Front Immunol 2012;3:396
133. Andrade D, Serra R, Svensjo E, et al. Trypanosoma cruzi invades host cells through the activation of endothelin and bradykinin receptors: a converging pathway leading to chagasic vasculopathy. Br J Pharmacol 2012;165:1333-47
134. Monteiro AC, Schmitz V, Morrot A, et al. Bradykinin B2 Receptors of dendritic cells, acting as sensors of kinins proteolytically released by Trypanosoma cruzi, are critical for the development of protective type-1 responses. PLoS Pathog 2007;3:e185
135. Lai J, Luo MC, Chen Q, et al. Dynorphin A activates bradykinin receptors to maintain neuropathic pain. Nat Neurosci 2006;9:1534-40
136. Grastilleur S, Mouledous L, Bedel J, et al. Role of kinin B2 receptors in opioid-induced-hyperalgesia in inflammatory pain in mice. Biol Chem 2013;394:361-8
137. Kunz M, Nussberger J, Holtmannspoetter M, et al. Bradykinin in blood and CSF after acute cerebral lesions-correlations with cerebral edema and intracranial pressure. J Neurotrauma 2013; Epub ahead of print
138. Austinat M, Braeuninger S, Pesquero JB, et al. Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke 2009;40 285-93
139. Trabold R, Eros C, Zweckberger K, et al. The role of bradykinin B(1) and B (2) receptors for secondary brain damage after traumatic brain injury in mice. J Cereb Blood Flow Metab 2010;30:130-9
140. Guevara-Lora I. Kinin-mediated inflammation in neurodegenerative disorders. Neurochem Int 2012;61:72-8
141. Prediger RD, Medeiros R, Pandolfo P, et al. Genetic deletion or antagonism of kinin B(1) and B(2) receptors improves cognitive deficits in a mouse model of Alzheimer's disease. Neuroscience 2008;151:631-43
142. Viel TA, Buck HS. Kallikrein-kinin system mediated inflammation in Alzheimer's disease in vivo. Curr Alzheimer Res 2011;8:59-66
143. Trujillo CA, Negraes PD, Schwindt TT, et al. Kinin-B2 receptor activity determines the differentiation fate of neural stem cells. J Biol Chem 2012;287:44046-61
144. Cote J, Savard M, Bovenzi V, et al. Selective tumor blood-brain barrier opening with the kinin B2 receptor agonist [Phe(8)psi(CH(2)NH)Arg(9)]-BK in a F98 glioma rat model: an MRI study. Neuropeptides 2010;44:177-85
145. Cote J, Savard M, Neugebauer W, et al. Dual kinin B1 and B2 receptor activation provides enhanced blood-brain barrier permeability and anticancer drug delivery into brain tumors. Cancer Biol Ther 2013;14(9; Epub ahead of print
146. Dabire H, Barthelemy I, Blanchard-Gutton N, et al. Vascular endothelial dysfunction in Duchenne muscular dystrophy is restored by bradykinin through upregulation of eNOS and nNOS. Basic Res Cardiol 2012;107 240-6
147. Su JB, Cazorla O, Blot S, et al. Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy. Cardiovasc Res 2012;95:86-96
148. Bas M. Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial. Expert Rev Clin Immunol 2012;8:707-17
149. Morissette G, Houle S, Gera L, et al. Antagonist, partial agonist and antiproliferative actions of B-9870 (CU201) as a function of the expression and density of the bradykinin B1 and B2 receptors. Br J Pharmacol 2007;150:369-79
150. Zhang X, Lowry JL, Brovkovych V, Skidgel RA. Characterization of dual agonists for kinin B1 and B2 receptors and their biased activation of B2 receptors. Cell Signal 2012;24:1619-31